A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.

Gribaleva E, Krogh NS, Prieto-Merino D, Coker B, Jackson A, Akkoc A, Birkner T, Bruninx E, Hennessy C, Chan K, Cutlar L, Farrell B, Fletcher G, Gerbens L, Frostrup AG, Henrohn D, Hyseni A, Irvine AD, Malek R, McCarthy C, Vittrup I, Ouwerkerk W, Randall R, Spuls PI, Thomsen SF, Wall D, Weidinger S, Werfel T, Schmitt J, Flohr C

Open source

DOI: 10.1093/skinhd/vzaf020
Published: 2025 Jun
Container: Skin health and disease
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/skinhd/vzaf020,
  title = {A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.},
  author = {Gribaleva E and Krogh NS and Prieto-Merino D and Coker B and Jackson A and Akkoc A and Birkner T and Bruninx E and Hennessy C and Chan K and Cutlar L and Farrell B and Fletcher G and Gerbens L and Frostrup AG and Henrohn D and Hyseni A and Irvine AD and Malek R and McCarthy C and Vittrup I and Ouwerkerk W and Randall R and Spuls PI and Thomsen SF and Wall D and Weidinger S and Werfel T and Schmitt J and Flohr C},
  year = {2025},
  journal = {Skin health and disease},
  doi = {10.1093/skinhd/vzaf020},
  url = {https://doi.org/10.1093/skinhd/vzaf020}
}

RIS

TY  - JOUR
TI  - A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.
AU  - Gribaleva E
AU  - Krogh NS
AU  - Prieto-Merino D
AU  - Coker B
AU  - Jackson A
AU  - Akkoc A
AU  - Birkner T
AU  - Bruninx E
AU  - Hennessy C
AU  - Chan K
AU  - Cutlar L
AU  - Farrell B
AU  - Fletcher G
AU  - Gerbens L
AU  - Frostrup AG
AU  - Henrohn D
AU  - Hyseni A
AU  - Irvine AD
AU  - Malek R
AU  - McCarthy C
AU  - Vittrup I
AU  - Ouwerkerk W
AU  - Randall R
AU  - Spuls PI
AU  - Thomsen SF
AU  - Wall D
AU  - Weidinger S
AU  - Werfel T
AU  - Schmitt J
AU  - Flohr C
PY  - 2025
JO  - Skin health and disease
DO  - 10.1093/skinhd/vzaf020
UR  - https://doi.org/10.1093/skinhd/vzaf020
ER  -

APA

E, G., NS, K., D, P., B, C., A, J., A, A., T, B., E, B., C, H., K, C., L, C., B, F., G, F., L, G., AG, F., D, H., A, H., AD, I., R, M., C, M., I, V., W, O., R, R., PI, S., SF, T., D, W., S, W., T, W., J, S., & C, F. (2025). A pan-European register-based observational study of abrocitinib and conventional systemic therapies in moderate and severe atopic dermatitis: the DREAM TO TREAT AD study protocol.. Skin health and disease. https://doi.org/10.1093/skinhd/vzaf020

Source records

pubmed · retrieved 2026-09-26T02:25:55.550Z